Linkler & Kaynaklar - Aferez Derneği

TÜRKİYE'DEKİ AFEREZ MERKEZLERİ

Güncel merkez listesi ve iletişim bilgileri

ÜLKEMİZDE TERAPÖTİK AFEREZ YAYINLARI

Son yıllarda yayınlanmış bilimsel çalışmalar

1: Yüksel MK, İlhan O. JACIE: A 20 year-old voluntary body functioning worldwide. Transfus Apher Sci. 2018 Apr;57(2):153-158. doi: 10.1016/j.transci.2018.04.012.

2: Yıldız S, Demirkan F. What is the evidence for the role of therapeutic apheresis in the management of complement-associated thrombotic microangiopathies? Transfus Apher Sci. 2018 Feb;57(1):31-34.

3: Tekgündüz E, et al. A multicenter experience of thrombotic microangiopathies in Turkey: The Turkish Hematology Research and Education Group (ThREG)-TMA01 study. Transfus Apher Sci. 2018 Feb;57(1):27-30.

4: Apaydin S. The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis. Transfus Apher Sci. 2018 Feb;57(1):8-12.

5: Tekgunduz SA, Kara A, Bozkaya IO, Cagli A, Ozbek NY. Therapeutic plasma exchange in non-hematooncological disorders in pediatrics: A single center experience. Transfus Apher Sci. 2018 Feb;57(1):20-22.

6: Demirkan F, Tekgündüz E. Application of apheresis science in Emergency Medicine. Transfus Apher Sci. 2018 Feb;57(1):1.

7: Gurlek Gokcebay D, Akpinar Tekgunduz S. Granulocyte transfusions in the management of neutropenic fever: A pediatric perspective. Transfus Apher Sci. 2018 Feb;57(1):16-19.

8: Özgür G, Beyan C. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. Transfus Apher Sci. 2018 Feb;57(1):13-15.

9: Kalayoglu-Besisik S. The use of emergency apheresis in the management of plasma cell disorders. Transfus Apher Sci. 2018 Feb;57(1):35-39.

10: Korkmaz S. The management of hyperleukocytosis in 2017: Do we still need leukapheresis? Transfus Apher Sci. 2018 Feb;57(1):4-7.

11: Demirsoy ET, et al. Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura. Transfus Apher Sci. 2018 Apr;57(2):222-224.

12: Sevindik OG, Korkmaz S, Altuntas F. Current status of art mobilization in Myeloma. Transfus Apher Sci. 2017 Dec;56(6):850-853.

13: Yilmaz F, et al. Risk factors for poor mobilization in solid tumors: How effectively can we mobilize patients with solid tumors? Transfus Apher Sci. 2017 Dec;56(6):809-813.

14: Goren Sahin D, Arat M. Peripheral blood stem cell collection for allogeneic hematopoietic stem cell transplantation. Transfus Apher Sci. 2017 Dec;56(6):800-803.

15: Altuntaş F, Korkmaz S. Hematopoietic progenitor cell mobilization. Transfus Apher Sci. 2017 Dec;56(6):787.

16: Kayıkçı Ö, et al. Biosimilar filgrastim efficacy in steady-state hematopoietic progenitor cell mobilization. Transfus Apher Sci. 2017 Dec;56(6):832-835.

17: Karasu G, Uygun V, Yesilipek A. Factors associated with peripheral blood stem cell yield in healthy pediatric donors. Transfus Apher Sci. 2017 Dec;56(6):819-824.

18: Kiki I. What is the role of apheresis technology in stem cell transplantation? Transfus Apher Sci. 2017 Dec;56(6):788-794.

19: Namdaroglu S, Korkmaz S, Altuntas F. Management of mobilization failure in 2017. Transfus Apher Sci. 2017 Dec;56(6):836-844.

20: Dogu MH, et al. Autologous stem cell transplantation and stem cell mobilization kinetics in elderly patients. Transfus Apher Sci. 2017 Dec;56(6):814-818.

21: Korkmaz S, Altuntas F. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present? Transfus Apher Sci. 2017 Dec;56(6):795-799.

22: Aksu T, et al. Two versus three day upfront use of granulocyte-colony stimulating factor in healthy bone marrow donors. Transfus Apher Sci. 2017 Dec;56(6):829-831.

23: Ocakci S, Kahraman S, Cagirgan S. Age does not matter: Mobilization and harvesting are safe and effective for elderly donors. Transfus Apher Sci. 2017 Dec;56(6):825-828.

24: Malkan UY, Ozcebe OI. Leukapheresis do not improve early death rates in AML patients with hyperleukocytosis. Transfus Apher Sci. 2017 Dec;56(6):880-882.

25: Tekgündüz E, et al. Autologous hematopoietic progenitor cell mobilization: A position-statement from TSA. Transfus Apher Sci. 2017 Dec;56(6):845-849.

26: Tekgündüz E, et al. Current practice of autologous hematopoietic progenitor cell mobilization: Results of a survey. Transfus Apher Sci. 2017 Dec;56(6):804-808.

27: Özkurt ZN, et al. Factors affecting hematopoietic stem cell mobilization and apheresis in allogeneic donors. Transfus Apher Sci. 2017 Jun;56(3):470-473.

28: Gerçeker E, et al. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci. 2017 Jun;56(3):421-426.

29: Ataca Atilla P, et al. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci. 2017 Apr;56(2):190-198.

2016 TERAPÖTİK AFEREZ REHBERİ

Klinik uygulama ve prosedür rehberi

Gitmek İçin Tıklayın

OTOLOG KÖK HÜCRE MOBİLİZASYONU

Pratik yaklaşım ve uygulama esasları

Gitmek İçin Tıklayın

TERAPÖTİK AFEREZ YÖNETMELİĞİ

Resmi gazete ve güncel mevzuat

Gitmek İçin Tıklayın

LİNKLER & KAYNAKLAR

TÜRKİYE'DEKİ AFEREZ MERKEZLERİ

ÜLKEMİZDE TERAPÖTİK AFEREZ YAYINLARI

2016 TERAPÖTİK AFEREZ REHBERİ

OTOLOG KÖK HÜCRE MOBİLİZASYONU

TERAPÖTİK AFEREZ YÖNETMELİĞİ

DİĞER LİNKLER